Milestone Pharmaceuticals announced the resubmission of its New Drug Application, NDA, to the U.S. Food and Drug Administration, FDA, for etripamil, the Company’s lead investigational product for the management of paroxysmal supraventricular tachycardia, PSVT. “We appreciate FDA’s guidance through the resubmission process. We believe we have addressed all the issues raised in the Refusal to File letter and look forward to working with the Agency as it reviews our application,” said Joseph Oliveto, President, and Chief Executive Officer of Milestone Pharmaceuticals. “If approved, we believe that etripamil nasal spray will be a valuable treatment option for patients suffering from PSVT.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIST:
- Milestone Pharmaceuticals Advances Etripamil Development
- Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
- Milestone Pharmaceuticals reports FY23 EPS ($1.39), consensus ($1.37)
- Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference
- Biotech Alert: Searches spiking for these stocks today
